BioLife to Showcase Oral Peptide Delivery Technology During London Life Sciences Week
3.11.2026 17:03:00 EET | Business Wire | Press release
BioLife Products Limited today announced its participation in London Life Sciences Week, where it will highlight its patented oral peptide delivery technology and recent advances in its intellectual property portfolio.
BioLife will present at the LSX Investival Showcase on Monday, November 16, 2026, from 3:15 to 3:30 p.m. GMT, at Old Billingsgate, London. The presentation will be led by Former US Ambassador James P. Cain, Strategic Advisor to the Chairman & Founder, alongside Ludivine Delattre, Business and Corporate Relations, and will highlight the scientific journey behind the technology and its potential applications.
BioLife is focused on developing a novel approach to delivering peptide therapeutics orally. Built on over 35 years of pharmaceutical effervescence expertise and two decades of oral peptide research by founder and inventor Dr. Farid Bennis, the technology uses a dissolvable effervescent tablet to create a buffered solution that helps protect peptides during gastrointestinal transit and support systemic delivery.
"The rapid evolution of peptide medicines continues to create opportunities for innovation in drug delivery," said Dr. Farid Bennis, Founder of BioLife. "Our work reflects many years of research into the challenges of oral peptide delivery. London Life Sciences Week provides an important opportunity to share our progress and explore the potential of this approach with those advancing the next generation of peptide therapeutics."
Preclinical studies have demonstrated measurable systemic semaglutide exposure following oral administration, providing in vivo proof of concept. Combined with earlier human clinical research involving oral insulin formulations, these findings provide a scientific foundation for further investigation across additional peptide medicines, subject to further validation.
BioLife's technology is supported by granted patents in the United States and France, with additional international filings progressing. Its U.S. patent includes claims covering multiple GLP-1 receptor agonists, including semaglutide, liraglutide, dulaglutide, albiglutide, exenatide and lixisenatide, with protection extending into 2042.
About the Technology
BioLife's patented effervescent peptide delivery technology uses a dissolvable tablet to create a buffered solution designed to help protect peptide medicines during gastrointestinal transit and support systemic delivery. Preclinical studies have demonstrated measurable systemic semaglutide exposure following oral administration.
The development programme builds on nearly 20 years of research, including human clinical studies with oral insulin formulations and work with Charles River Laboratories, SGS, Eurofins/Amatsi and Cephac. The technology is in development and is not approved for the treatment of any disease.
About BioLife
BioLife develops oral delivery technologies for peptide medicines, combining expertise in pharmaceutical effervescence, formulation science and oral peptide research. The company's technology portfolio and related patent estate have been independently developed and are wholly owned.
Website: https://biolife.bio/
View source version on businesswire.com: https://www.businesswire.com/news/home/20261103294487/en/
Contacts
For Enquiries Contact
James P. Cain
U.S. Ambassador (Ret.)
Strategic Advisor to the Chairman & Founder
BioLife Products Limited
jpc@biolife.bio
Ludivine Delattre
Business and Corporate Relations
BioLife Products Limited
ld@biolife.bio
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sceye and SoftBank Corp. Sign Agreement for Fleet of Stratospheric Platforms Targeting Nationwide Coverage in Japan3.11.2026 17:00:00 EET | Press release
Sceye, a U.S. aerospace and material science company building High Altitude Platform Systems (HAPS) for stratospheric infrastructure, today announced a five-year Master Services Agreement (MSA) with SoftBank Corp. (TOKYO:9434, “SoftBank”) to manufacture, launch, and operate a fleet of Sceye’s HAPS over Japan with the aim of achieving nationwide coverage. This agreement advances the companies’ partnership from flight demonstrations toward full-scale stratospheric infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103391128/en/ Sceye and SoftBank Corp. Sign Agreement for Fleet of Stratospheric Platforms Targeting Nationwide Coverage in Japan Sceye’s HAPS will form a key pillar of SoftBank’s strategy for a Ubiquitous Network. The majority of Sceye’s initial fleet will provide mobile broadband throughout Japan, while a subset will also establish a Free Space Optical (FSO) network in the stratosphere. These deploym
SharkNinja Brings Its All-Star Neighbors and Fans Home for the Holidays3.11.2026 17:00:00 EET | Press release
SharkNinja, Inc. (NYSE: SN), a global product design and technology company, today unveiled the final spot in its first-ever SharkNinja holiday campaign, starring global brand ambassadors David Beckham, Tom Brady, Kevin Hart, and Aryna Sabalenka. The campaign, “There’s No Home Like a SharkNinja Home,” puts the ambassadors’ own fandom and love of Shark and Ninja products at the center of a holiday house-sitting assignment that gets a little out of hand and invites fans along for the fun. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103325477/en/ David Beckham, Tom Brady, Kevin Hart, and Aryna Sabalenka celebrate a shared love and fandom of Shark and Ninja products in SharkNinja’s first-ever holiday campaign, “There’s No Home Like a SharkNinja Home” Created by SharkNinja’s in-house Creative Labs team and produced by Studio 99, the holiday campaign builds on SharkNinja’s Neighbors series, which debuted in 2025 with Beckham
Andersen Consulting Enhances Transformation Capabilities with Bakia Consulting3.11.2026 16:30:00 EET | Press release
Andersen Consulting advances its business transformation capabilities through a Collaboration Agreement with Bakia Consulting, a firm specializing in finance function transformation. Headquartered in Paris with capabilities in Singapore and Hong Kong, Bakia Consulting has helped large corporations and financial institutions redesign their finance functions, addressing operating models, organizational structures, processes, and digital systems. The firm combines project management and change management, working alongside clients to develop solutions and sustain change. Bakia Consulting also advises on financial and non-financial management models, process optimization, and digital tools. “Finance functions are being asked to deliver better insight, operate more efficiently, and adapt to changing business needs, often at the same time,” said Romain Dubuisson, partner at Bakia Consulting. “We work closely with clients to develop solutions that reflect their operational realities, combinin
Organigram to Acquire Aurora and Establish a Global Cannabis Leader3.11.2026 16:16:00 EET | Press release
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (“Organigram”) and Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) (“Aurora”) today announced that they have entered into an arrangement agreement (the “Arrangement Agreement”) pursuant to which Organigram will acquire all of the issued and outstanding common shares (the “Aurora Shares”) of Aurora at a price of C$7.80 per Aurora Common Share (the “Transaction”). The Transaction values Aurora at approximately C$561 million on a fully diluted equity value basis. The consideration represents a 93% premium to the unaffected closing share price of Aurora Shares on the TSX as of August 10, 2026, the last full trading day of Aurora prior to the announcement by Curaleaf Holdings, Inc. (“Curaleaf”) of its intention to launch a hostile takeover bid for Aurora (the “Unaffected Price”), and a 21% premium relative to the current bid value of the Curaleaf hostile offer3 (the “Hostile Bid”) as most recently amended on October 6, 2026, which was unanimousl
CoStar Group Opens Nominations for Its Sixth Annual CoStar Impact Awards3.11.2026 16:00:00 EET | Press release
CoStar Group (NASDAQ: CSGP), a leading provider of online real estate marketplaces, information, analytics and digital twins in the property markets, has opened nominations for the sixth annual CoStar Impact Awards. The CoStar Impact Awards celebrate commercial property projects and transactions that have made a significant impact in neighbourhoods or submarkets across 129 major international markets in the United Kingdom, the United States and Canada. The awards will recognize outstanding projects and transactions completed in 2026, as selected by a panel of sector professionals representing each respective market. Judges panels comprised of commercial property industry professionals will select winners from each market in the United Kingdom based on the following categories: Lease of the Year, Commercial Development of the Year and Sale/Acquisition of the Year. As part of the assessment process, judges will look to identify the most influential projects that demonstrate growth, creat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom